BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 17640917)

  • 1. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
    Lu J; Chew EH; Holmgren A
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The thioredoxin antioxidant system.
    Lu J; Holmgren A
    Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
    Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
    Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
    Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
    Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate.
    Zhang H; Cao D; Cui W; Ji M; Qian X; Zhong L
    Free Radic Biol Med; 2010 Dec; 49(12):2010-8. PubMed ID: 20951799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo.
    Fang J; Holmgren A
    J Am Chem Soc; 2006 Feb; 128(6):1879-85. PubMed ID: 16464088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
    Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
    Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Thioredoxin System for Cancer Therapy.
    Zhang J; Li X; Han X; Liu R; Fang J
    Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione.
    Lu J; Vlamis-Gardikas A; Kandasamy K; Zhao R; Gustafsson TN; Engstrand L; Hoffner S; Engman L; Holmgren A
    FASEB J; 2013 Apr; 27(4):1394-403. PubMed ID: 23248236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant.
    Zhao R; Masayasu H; Holmgren A
    Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8579-84. PubMed ID: 12070343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
    Chew EH; Lu J; Bradshaw TD; Holmgren A
    FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
    Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
    Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
    Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
    Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
    You BR; Park WH
    Oncol Rep; 2012 Aug; 28(2):749-57. PubMed ID: 22684917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
    Wang X; Zhang J; Xu T
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.
    Zheng CY; Lam SK; Li YY; Ho JC
    Int J Oncol; 2015 Mar; 46(3):1067-78. PubMed ID: 25572414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
    Arnér ES; Nakamura H; Sasada T; Yodoi J; Holmgren A; Spyrou G
    Free Radic Biol Med; 2001 Nov; 31(10):1170-8. PubMed ID: 11705695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
    Montano SJ; Lu J; Gustafsson TN; Holmgren A
    Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
    Huang J; Xu J; Tian L; Zhong L
    Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.